Related Experiment Video
Updated: Jan 3, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies
Prioty Islam1, Anthony R Mato2
1From the Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Abstract:
The landscape of chronic lymphocytic leukemia has transformed in the era of small molecule inhibitor targeted therapies. While randomized controlled trials remain the criterion standard in evaluating new therapies, they are often unable to keep pace with the clinical questions that arise during the use of novel agents. Real-world evidence is generated through analysis of data such as electronic medical records, payer claims, and patient registry databases and can provide invaluable information to supplement randomized controlled trials, such as outcomes in patient populations excluded from clinical trials, rates of discontinuation or dose reductions in clinical practice, survival outcomes, and optimal sequencing of novel agents. This review aims to discuss major findings from recent, relevant, real-world evidence publications that have greatly informed our understanding of chronic lymphocytic leukemia as it is treated in clinical practice.
Insights
Real-world evidence complements clinical trials for chronic lymphocytic leukemia (CLL) treatment. It offers insights into patient outcomes and treatment patterns with novel targeted therapies in clinical practice.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) treatment has evolved with targeted small molecule inhibitors.
- Randomized controlled trials (RCTs) are standard but may not address all clinical questions for novel agents.
- Real-world evidence (RWE) provides crucial data beyond RCTs.
Purpose of the Study:
- To review key findings from recent RWE publications on CLL treatment.
- To highlight how RWE informs clinical practice and understanding of novel therapies.
- To discuss the role of RWE in supplementing RCTs for CLL management.
Main Methods:
- Analysis of electronic medical records, payer claims, and patient registries.
- Review of recent, relevant publications utilizing real-world data.
- Synthesis of findings related to patient populations, treatment patterns, and outcomes.
Main Results:
- RWE reveals outcomes in diverse patient groups often excluded from RCTs.
- Data show practical aspects like discontinuation rates and dose adjustments in clinical settings.
- RWE informs survival outcomes and optimal sequencing of novel CLL therapies.
Conclusions:
- Real-world evidence significantly enhances the understanding of CLL treatment in clinical practice.
- RWE provides valuable insights into the application and effectiveness of targeted therapies.
- Integrating RWE with RCT data optimizes patient care and therapeutic strategies for CLL.
